Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

658 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.
Conte P, Schneeweiss A, Loibl S, Mamounas EP, von Minckwitz G, Mano MS, Untch M, Huang CS, Wolmark N, Rastogi P, D'Hondt V, Redondo A, Stamatovic L, Bonnefoi H, Castro-Salguero H, Fischer HH, Wahl T, Song C, Boulet T, Trask P, Geyer CE Jr. Conte P, et al. Among authors: schneeweiss a. Cancer. 2020 Jul 1;126(13):3132-3139. doi: 10.1002/cncr.32873. Epub 2020 Apr 14. Cancer. 2020. PMID: 32286687 Free PMC article. Clinical Trial.
Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
Hohaus S, Funk L, Martin S, Schlenk RF, Abdallah A, Hahn U, Egerer G, Goldschmidt H, Schneeweiss A, Fersis N, Kaul S, Wallwiener D, Bastert G, Haas R. Hohaus S, et al. Among authors: schneeweiss a. Br J Cancer. 1999 Mar;79(9-10):1500-7. doi: 10.1038/sj.bjc.6690239. Br J Cancer. 1999. PMID: 10188897 Free PMC article.
[Systemic therapy of operable carcinoma of the breast].
Kaufmann M, Jonat W, Eiermann W, Costa S, Hilfrich J, Jänicke F, Beckmann MW, Wallwiener D, Gerber B, Rody A, Schneeweiss A, Nitz U, Köhler U, von Minckwitz G. Kaufmann M, et al. Among authors: schneeweiss a. Zentralbl Gynakol. 2005 Aug;127(4):207-12. doi: 10.1055/s-2005-836524. Zentralbl Gynakol. 2005. PMID: 16037900 German. No abstract available.
Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study.
Rupp U, Schoendorf-Holland E, Eichbaum M, Schuetz F, Lauschner I, Schmidt P, Staab A, Hanft G, Huober J, Sinn HP, Sohn C, Schneeweiss A. Rupp U, et al. Among authors: schneeweiss a. Anticancer Drugs. 2007 Apr;18(4):477-85. doi: 10.1097/CAD.0b013e32801403f4. Anticancer Drugs. 2007. PMID: 17351401 Clinical Trial.
Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/ cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer: a randomized phase II trial.
Schneeweiss A, Lauschner I, Ruiz A, Guerrero A, Sánchez-Rovira P, Seguí MA, Goerke K, Wolf M, Manikhas AG, Wacker J, Marmé F, Lichter P, Sinn HP, Sohn C, Mansouri K, Bauknecht T, Hahn M. Schneeweiss A, et al. Clin Breast Cancer. 2007 Apr;7(7):555-8. doi: 10.3816/CBC.2007.n.011. Clin Breast Cancer. 2007. PMID: 17509164 Clinical Trial.
658 results